What this means
This trial plans to compare two spots for a botulinum toxin shot. The people in it have not started yet, so no results exist.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 18–60 · 266 adults, planned
- Where
- Not listed
The science
- Registered title
- Botulinum Toxin Type A Injection Sites for Oral Commissure Ptosis
- Trial ID
- NCT07646886 ↗
- Phase
- PHASE 4
- Study type
- interventional
- Conditions
- Facial Aging, Melomental Folds, Oral Commissure Ptosis
- What is tested
- OnabotulinumtoxinA (Upper Depressor Anguli Oris Injection), OnabotulinumtoxinA (Lower Depressor Anguli Oris Injection)
- Sponsor
- Peking University
- Ages
- 18 Years to 60 Years
- Dates
- First posted Jun 15, 2026 · updated Jul 7, 2026
Registry summary
This multicenter, prospective, randomized parallel-controlled, assessor-blinded clinical trial aims to address the core clinical pain point of lack of high-level evidence and non-standardized operation in injection site selection for BTX-A treatment of oral commissure ptosis. A total of 266 eligible subjects will be randomly assigned in a 1:1 ratio to receive either upper DAO or lower DAO BTX-A injection. The study will compare the clinical efficacy, time-effect characteristics and safety profiles of the two regimens, and conduct stratified analysis of treatment response in different patient subtypes. The results will determine the optimal injection site for Chinese population, establish standardized operation specifications, fill the international evidence gap, and provide level I evidence for clinical practice.